Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Oral Microbiome in Alcohol Use Disorder during inpatient treatment

PROVIDER: PRJNA659632 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12531302.fastq.gz	Fastqsanger.gz
	SRR12531303.fastq.gz	Fastqsanger.gz
	SRR12531304.fastq.gz	Fastqsanger.gz
	SRR12531305.fastq.gz	Fastqsanger.gz
	SRR12531306.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 90

Similar Datasets

Plasma TNFSF10B levels associated with acamprosate treatment response in patients with alcohol use disorder

Project description:Acamprosate is an anti-craving drug used in alcohol use disorder (AUD) pharmacotherapy. However, only a subset of patients achieves optimal treatment outcomes. The identification of predictive biomarkers of acamprosate treatment response in patients with AUD would be a substantial advance in addiction medicine. We designed this study to use proteomics data as a quantitative biological trait as a step toward identifying inflammatory modulators that might be associated with acamprosate treatment outcomes. The NIAAA-funded Mayo Clinic Center for the Individualized Treatment of Alcoholism study had previously recruited 442 AUD patients who received three months of acamprosate treatment. However, only 267 subjects returned for the 3-month follow-up visit and, as a result, had treatment outcome information available. Baseline alcohol craving intensity was the most significant predictor of acamprosate treatment outcomes. Baseline plasma TNFSF10 concentration was associated with alcohol craving intensity and variation in acamprosate treatment outcomes among AUD patients. We also performed RNA sequencing using baseline peripheral blood mononuclear cells from AUD patients with known acamprosate treatment outcomes which revealed that inflammation-related pathways were highly associated with relapse to alcohol use during the three months of acamprosate treatment. These observations represent an important step toward advancing our understanding of the pathophysiology of AUD and molecular mechanisms associated with acamprosate treatment response. In conclusion, applying omics-based approaches may be a practical approach for identifying biologic markers that could potentially predict alcohol craving intensity and acamprosate treatment response.

2022-09-21 | GSE208132 | GEO

Project description:Functional Microbial Responses to Alcohol Abstinence in Patients with Alcohol Use Disorder

| PRJNA613834 | ENA

Acamprosate, Craving and Alcohol Use Disorder: the Role of Inflammation

Project description:The present study utilized patient-derived “cell-line” model systems treated with anti-craving drugs that are used to treat alcohol use disorder (AUD) as “molecular probes” to help identify molecular mechanisms associated with craving and AUD treatment outcomes.

2024-04-03 | GSE213380 | GEO

human gut mycobiome

Project description:Human intestinal mycobiome in alcohol use disorder Targeted loci

| PRJNA703732 | ENA

Epigenetic Moderators of Naltrexone Efficacy for Alcohol Use Disorder

Project description:Epigenetic Moderators of Naltrexone Efficacy for Alcohol Use Disorder

| PRJNA729134 | ENA

Epigenetic Moderators of Naltrexone Efficacy for Alcohol Use Disorder

Project description:Epigenetic Moderators of Naltrexone Efficacy for Alcohol Use Disorder

| PRJNA729135 | ENA

Plasma TNFSF10B levels associated with acamprosate treatment response in patients with alcohol use disorder

Project description:Plasma TNFSF10B levels associated with acamprosate treatment response in patients with alcohol use disorder

| PRJNA858444 | ENA

Project description:Gene expression differences of alcohol use disorder in human brain

| PRJNA1062742 | ENA

Acamprosate, Craving and Alcohol Use Disorder: the Role of Inflammation

Project description:Acamprosate, Craving and Alcohol Use Disorder: the Role of Inflammation

| PRJNA880849 | ENA

Profiling of mRNA transcriptomic changes using RNA-seq in postmortem putamen of subjects with alcohol use disorder

Project description:Purpose: The goal of this study to examine mRNA transcriptomic changes in reward-related brain regions of subjects with alcohol use disorder. Methods: Total RNAs were extracted from postmortem putamen of 12 AUD and 12 control subjects. rRNA depletion RNA sequencing was performed and the sequence reads were processed using the bulk RNA-seq processing pipeline Pipeliner workflow (Federico et al. Front Genet 2019; 10, 614). AUD-associated mRNA transcriptomic changes were analyzed by the Limma-Voom method. Results: Differentially expressed mRNAs (absolute FC>2.0 & P<0.05) were identified in postmortem putamen of subjects with alcohol use disorder (AUD). Chronic alcohol consumption may alter mRNA transcriptome profiles in reward-related brain regions, resulting in alcohol-induced neuroadaptations.

2021-10-13 | GSE182440 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data